Raluca Ionescu-Ittu
Manager
Montreal
Education
Ph.D. and M.S., epidemiology, McGill University; B.A., social work, Bucharest University
Summary of Experience
Dr. Ionescu-Ittu is a quantitative epidemiologist with expertise in comparative effectiveness methods and study designs for observational studies of drug effects. She has experience working with medical claims, chart review, and clinical trial data to study the incidence and prevalence of diseases, the risks and benefits of medications, and health resource utilization and health care costs. Her clinical areas of expertise include oncology, congenital heart disease, cardiology, and immune diseases. Dr. Ionescu-Ittu joined Analysis Group in 2012 after completing a one-year postdoctoral research program at Harvard University.
Selected Publishing
-
Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study
Future Oncology. 2019 Feb;15(4):359-370
2019Tarhini A, Ghate S, Ionescu-Ittu R, Shi S, Nakasato A, Ndife B, Laliberté F, Burne R, Duh MS
-
Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy
Lung Cancer. May 2018;119:112-119
2018Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M, Ionescu-Ittu R
-
Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center
International Urology and Nephrology. Mar 2018;50(3):459-467
2018Ruud Bosch JLH, Vekeman F, Duh MS, Neary M, Magestro M, Fortier J, Karner P, Ionescu-Ittu R, Zonnenberg BA
-
Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus
PLOS ONE. Nov 15 2018; 13(11): p. e0204646
2018Zonnenberg BA, Neary MP, Duh MS, Ionescu-Ittu R, Fortier J, Vekeman F
-
Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication
BMC Infectious Diseases, 2018 Aug 29;18(1):438
2018Vekeman F, Weiss L, Aram J, Ionescu-Ittu R, Moosavi S, Xiao Y, Cheng WY, Bhak RH, Tawadrous M, Capparella MR, Montravers P, Duh MS
-
Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy
Current Medical Research and Opinion. 2018 Dec;34(12):2169-2176
2018Ghate SR, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS
-
Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive
Melanoma Research, October 9, 2018
2018Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS
-
Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer
Clinical Lung Cancer. Nov 2017;18(6):640-650 e642
2017Ganti AK, Hirsch FR, Wynes MW, Ravelo A, Ramalingam SS, Ionescu-Ittu R, Pivneva I, Borghaei H
-
Overall survival in patients with glioblastoma before and after bevacizumab approval
Current Medical Research and Opinion. May 2018;34(5):813-820
2017Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm J
-
Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma
Melanoma Research. 2018 Dec;28(6):618-628
Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberté F, Nakasato A, Burne R, Duh MS
News
-
April 16, 2018
-
August 18, 2016
-
August 10, 2016